Skip to content
DataLookout
Menu

NCT07947966

Safety and Drug Concentrations of REGN20566 in Adults With Overweight or Obesity

StatusNot Yet Recruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Endpoints

Primary

Occurrence of Treatment Emergent Adverse Events (TEAEs)
Timeframe: Up to 16 weeks
Severity of TEAEs
Timeframe: Up to 16 weeks
Occurrence of TEAEs
Timeframe: Up to 27 weeks

Secondary (4)

Concentration of REGN20566 in serum
Occurrence of Anti-Drug Antibodies (ADA) to REGN20566
Magnitude of ADA to REGN20566
Occurrence of ADA to REGN20566

Arms and interventions

Part AExperimental
Part BPlacebo comparator

Drugs: REGN20566, Placebo